|Bid||0.1850 x 0|
|Ask||0.1900 x 0|
|Day's Range||0.1850 - 0.1950|
|52 Week Range||0.1200 - 2.3000|
|Beta (5Y Monthly)||0.90|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||0.40|
Vancouver, British Columbia--(Newsfile Corp. - August 3, 2020) - Emerald Health Therapeutics, Inc. (TSXV: EMH) (OTCQX: EMHTF) ("Emerald") announces that it has issued an aggregate of 3,800,000 stock options to employees, consultants and directors at an exercise price of $0.21 per common share for a period of five years. All stock options will vest 25% on the date of grant and 25% on the first three anniversaries of the date of grant. Emerald ...
Vancouver, British Columbia--(Newsfile Corp. - July 31, 2020) - Emerald Health Therapeutics, Inc. (TSXV: EMH) ("Emerald") and Quinto Resources Inc. ("Quinto") (TSXV: QIT) today announced that they have entered into a share purchase agreement dated July 30, 2020 (the "Agreement") in respect of the sale of Emerald's wholly-owned subsidiaries, Verdelite Sciences, Inc. ("Verdelite Sciences") and Verdelite Property Holdings, Inc. ("Verdelite Property" and, together with Verdelite Sciences, the "Subsidiaries"). The Subsidiaries together own ...
VANCOUVER, July 15, 2020 -- Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) has terminated certain related party agreements pertaining to consulting.